Ignite Creation Date:
2025-12-25 @ 12:10 AM
Ignite Modification Date:
2025-12-25 @ 10:10 PM
Study NCT ID:
NCT01108458
Status:
TERMINATED
Last Update Posted:
2017-03-03
First Post:
2010-04-20
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Sponsor:
George Albert Fisher
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2010-07
Start Date Type:
None
Primary Completion Date:
2010-11
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-03
Completion Date Type:
ACTUAL
First Submit Date:
2010-04-20
First Submit QC Date:
None
Study First Post Date:
2010-04-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2017-01-12
Results First Submit QC Date:
None
Results First Post Date:
2017-03-03
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-01-12
Last Update Post Date:
2017-03-03
Last Update Post Date Type:
ACTUAL